Difference between revisions of "Fujiwara Y, et al. Cancer Sci. (2019) cited as Ref 640 in DOI: 10.1038/s41392-020-0110-5 (Q9903)"
Jump to navigation
Jump to search
(Created claim: Published In Name String (P102): Cancer Sci., #quickstatements; #temporary_batch_1590006349955) |
(Created claim: Page(s) (P105): 1715-1723, #quickstatements; #temporary_batch_1590074839150) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Property / Volume | |||
| + | 110 | ||
| Property / Volume: 110 / rank | |||
| + | Normal rank | ||
| Property / title | |||
| + | Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors (English) | ||
| Property / title: Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 1715-1723 | ||
| Property / Page(s): 1715-1723 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:47, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Fujiwara Y, et al. Cancer Sci. (2019) cited as Ref 640 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Fujiwara Y
0 references
2019
0 references
Cancer Sci.
0 references
110
0 references
Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors (English)
0 references
1715-1723
0 references
